中国全科医学2012，Vol.15Issue(6)：672-673,676,3.
替吉奥或卡培他滨联合顺铂治疗晚期胃癌临床疗效研究
Curative Effect Analysis of S-1 Combined with Cisplatin or Capecitabine Combined with Cisplatin in the Treatment of Advanced Gastric Cancer
巴楠 1吴敏 2王丽娟 2张红巧2
作者信息
- 1. 450001 河南省郑州市,郑州大学基础医学院
- 2. 郑州大学第五附属医院肿瘤科
- 折叠
摘要
Abstract
Objective To compare the safety and efficacy of S - 1 combined with cisplatin and capecitabine combined with cisplatin in the initial treatment for patients with advanced gastric cancer whose ECOG is 0 - 1. Methods Thirty - seven patients with advanced gastric cancer and with ECOG from 0 to 1 were randomly divided into two groups. Patients in SP group ( n = 18 ) received S - 1 80 mg · M · D ; Patients in XP group ( n = 19 ) received capecitabine 2 000 mg · M-2 · D -1; oral administration twice a day in both groups for 14 days; Both groups were given cisplatin 75 mg/m , ivgtt on day one. The course was twenty - one days in two groups. Results All patients were evaluable. SP group: CR 1 , PR 8 , SD 4, PD 5 ; XP group: CR 0, PR 8, SD 5, PD 6. The efficacy of the two groups showed no statistically significant difference ( P > 0. 05 ). TTP were 5.9 months and 5. 5 months respectively for each group [ HR = 0. 92, 95%Cl(0.72, 1.13), P = 0. 065 ], OS were 12. 4 months and 11. 9 months respectively for each group [HR=0.94, 95%Cl(0.78, 1.09), P = 0.06l] . The main untoward effects were myelosuppression, gastroenteric reaction and weakness. SP group showed a lower rate of untoward effects than XP group. SP group also showed a lower rate of Ⅲ- Ⅳ thrombocytopenia (5.6% vs 15.8%, x2 =4. 08, P = 0. 049 ) and hand -foot syndrome ( 0 vs 21. 1% , x2 =4. 25 , P =0. 046 ) than XP group. Conclusion The treatment of the two groups were evidently effective, with SP group having better tolerance. The regimen could be clinically recommended.关键词
胃肿瘤/替吉奥/卡培他滨/顺铂/治疗结果Key words
Stomach neoplasms/ S - 1 / Capecitabine/ Cisplatin/ Treatment outcome分类
医药卫生引用本文复制引用
巴楠,吴敏,王丽娟,张红巧..替吉奥或卡培他滨联合顺铂治疗晚期胃癌临床疗效研究[J].中国全科医学,2012,15(6):672-673,676,3.
